Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is curable in less than 50% of patients. Prognostic models based on pre-treatment characteristics, such as the International Prognostic Index (IPI), are currently used to predict outcome in DLBCL. However, clinical outcome models identify neither the molecular basis of clinical heterogeneity, nor specific therapeutic targets. We analyzed the expression of 6,817 genes in diagnostic tumor specimens from DLBCL patients who received cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)-based chemotherapy, and applied a supervised learning prediction method to identify cured versus fatal or refractory disease. The algorithm classified two categories of patients with very different five-year overall survival rates (70% versus 12%). The model also effectively delineated patients within specific IPI risk categories who were likely to be cured or to die of their disease. Genes implicated in DLBCL outcome included some that regulate responses to B-cell–receptor signaling, critical serine/threonine phosphorylation pathways and apoptosis. Our data indicate that supervised learning classification techniques can predict outcome in DLBCL and identify rational targets for intervention.

[1]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[2]  R. Levy,et al.  Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma , 1986, Cell.

[3]  I. Magrath,et al.  Non-Hodgkin's Lymphomas , 1990 .

[4]  Belur V. Dasarathy,et al.  Nearest neighbor (NN) norms: NN pattern classification techniques , 1991 .

[5]  W. Kolch,et al.  Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. , 1991, Journal of immunology.

[6]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[7]  S. Proctor,et al.  Non-Hodgkin's Lymphomas , 1994, British Journal of Cancer.

[8]  Umesh V. Vazirani,et al.  An Introduction to Computational Learning Theory , 1994 .

[9]  R. Testi,et al.  The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. , 1994, Immunology today.

[10]  E. Engleman,et al.  V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene. , 1995, Journal of immunology.

[11]  C. Heckler.  Applied Discriminant Analysis , 1995 .

[12]  11. Applied Discriminant Analysis , 1996 .

[13]  A. Tarakhovsky,et al.  Immunodeficiency in Protein Kinase Cβ-Deficient Mice , 1996, Science.

[14]  D. Goeddel,et al.  A death-domain-containing receptor that mediates apoptosis , 1996, Nature.

[15]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[16]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[17]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[18]  P. Chomez,et al.  Positive and negative thymic selection in T cell receptor‐transgenic mice correlate with Nur77 mRNA expression , 1997, European journal of immunology.

[19]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[20]  H. Joensuu,et al.  A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. , 1997, Blood.

[21]  R. Hardy,et al.  The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. , 1997, Gene.

[22]  A. López-Guillermo,et al.  Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[24]  D. Neuberg,et al.  A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. , 1998, Blood.

[25]  A. Lerner,et al.  Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. , 1998, Blood.

[26]  J. Monroe,et al.  Antigen receptor-induced signal transduction imbalances associated with the negative selection of immature B cells. , 1999, Journal of immunology.

[27]  D. Hoessli,et al.  Signal transduction via CD44: role of plasma membrane microdomains. , 1999, Leukemia & lymphoma.

[28]  Q Cheng,et al.  NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[30]  Y. Saunthararajah,et al.  Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. , 1999, Cancer research.

[31]  R. Rabin,et al.  A Role for the Tec Family Tyrosine Kinase Txk in T Cell Activation and Thymocyte Selection , 1999, The Journal of experimental medicine.

[32]  A. Winoto,et al.  Nur77 transcription activity correlates with its apoptotic function in vivo , 1999, European journal of immunology.

[33]  B. Teicher,et al.  Enzymatic rationale and preclinical support for a potent protein kinase C beta inhibitor in cancer therapy. , 1999, Advances in enzyme regulation.

[34]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Saeki,et al.  Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. , 1999, Journal of immunology.

[36]  K. Rajewsky,et al.  Cellular origin of human B-cell lymphomas. , 1999, The New England journal of medicine.

[37]  W. Zong,et al.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis , 1999 .

[38]  J. Armitage,et al.  International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Mesirov,et al.  Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Christensen,et al.  Suppression of human inflammatory cell function by subtype‐selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B , 1999, British journal of pharmacology.

[41]  J. Armitage,et al.  International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  H. Youn,et al.  Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2. , 1999, Science.

[43]  W. Greenhalf,et al.  Structural Basis of BFL-1 for Its Interaction with BAX and Its Anti-apoptotic Action in Mammalian and Yeast Cells* , 2000, The Journal of Biological Chemistry.

[44]  Jill P. Mesirov,et al.  Class prediction and discovery using gene expression data , 2000, RECOMB '00.

[45]  L. Resar,et al.  HMG-I/Y, a New c-Myc Target Gene and Potential Oncogene , 2000, Molecular and Cellular Biology.

[46]  A. Lerner,et al.  The cAMP Signaling Pathway as a Therapeutic Target in Lymphoid Malignancies , 2000, Leukemia & lymphoma.

[47]  BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. , 2000, Blood.

[48]  N. Tinari,et al.  Galectin‐3 overexpression protects from apoptosis by improving cell adhesion properties , 2000, International journal of cancer.

[49]  Sayan Mukherjee,et al.  Feature Selection for SVMs , 2000, NIPS.

[50]  John Calvin Reed,et al.  Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. , 2000, Science.

[51]  D. Louis,et al.  Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A , 2000, Leukemia.

[52]  R. Aguiar,et al.  BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. , 2000, Blood.

[53]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[54]  D Haussler,et al.  Knowledge-based analysis of microarray gene expression data by using support vector machines. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Jill P. Mesirov,et al.  Support Vector Machine Classification of Microarray Data , 2001 .

[56]  E. Jaffe,et al.  Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. , 2000, Blood.

[57]  G. Kroemer,et al.  Mitochondria--the Death Signal Integrators , 2000, Science.